LightAir IonFlow air purifier to effectively reduce the infectivity of viruses that mimic coronaviruses.
FREMONT, CA: The IrsiCaixa AIDS Research Institute carries out tests and presents a report which shows that LightAir's technology IonFlow neutralizes viruses that mimic SARS-CoV-1 and SARS-CoV-2 in drop form on surfaces. This proof can now be added to a seven-year scientific study from Karolinska Institute that previously illustrated the technology's effectiveness against airborne viruses and how it significantly mitigates the spread of infection.
The company measured out several versions of pseudoviruses that mimic the entry of various coronaviruses into cells. The conclusion is that the droplets on exposed surfaces, IonFlow technology, inhibit viral entry within 30 minutes. The ability of this technology to combat virus spreading should be further investigated. Not least in these times, and specifically given that this technology attacks the viral entry process so viruses can no longer infect human cells.
IrsiCaixa is a pioneering center for research into infectious diseases located in Spain. The use of their tests was to show if LightAir IonFlow high-density ionization neutralizes corona pseudoviruses like SARS-CoV-2, which causes the disease COVID19, and SARS-CoV-1, which causes the disease SARS.
It is both stimulating and gratifying that companies can supplement the previous in-depth study from Karolinska Institute, which clearly shows how technology prevents the spread of several viruses. There is little reason to suspect that the technology can't inhibit a virus. The company is proud to contribute to the reduction of viral infections in homes, offices, schools, and other shared spaces.
The test intended to evaluate the potential of inhibiting the viral entry of both SARS-1 and SARS-2 pseudoviruses, which is proof of the principle of the efficacy of this strategy against various coronaviruses. Pseudoviruses are manipulated in the lab to mimic viral entrance into cells and are considered ideal for testing the efficacy of antivirals, antibodies, or strategies aimed at inhibiting viral entry.